Iovance Biotherapeutics is a commercial-stage biopharmaceutical company pioneering the development and commercialization of tumor-infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. The company's approach harnesses the immune system's natural ability to recognize and attack cancer cells by isolating a patient's tumor-infiltrating lymphocytes, expanding them outside the body, and reinfusing them as a personalized, one-time treatment. Iovance's marketed product, Amtagvi (lifileucel), is the first FDA-approved autologous T-cell therapy for unresectable or metastatic melanoma, particularly for patients who have been treated with anti-PD-1 therapies. The company is advancing clinical programs investigating lifileucel and other TIL therapies across multiple advanced solid tumors, including cervical cancer, non-small cell lung cancer, endometrial cancer, and head and neck squamous cell carcinoma. Iovance manufactures its therapies at a state-of-the-art cell therapy center in Philadelphia using proprietary manufacturing processes and collaborates with leading research institutions and pharmaceutical partners to expand its pipeline.